Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROPOXYPHENE HYDROCHLORIDE vs DARVON
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Propoxyphene hydrochloride is a centrally acting opioid analgesic that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering perception of and response to pain.
Propoxyphene is a mu-opioid receptor agonist that inhibits ascending pain pathways by binding to opioid receptors in the CNS, altering pain perception. It also has weak local anesthetic effects.
Management of mild to moderate pain,Off-label: chronic pain (historical use)
Management of mild to moderate pain
65 mg orally every 4 hours as needed for pain; maximum 390 mg per day.
Propoxyphene hydrochloride (Darvon) for moderate to severe pain: 65 mg orally every 4 hours as needed; maximum 390 mg/day.
6–12 hours (parent drug); norpropoxyphene metabolite half-life 30–36 hours, accumulates with repeated dosing, increasing risk of toxicity, especially in elderly or renal impairment.
6-12 hours (parent drug); norpropoxyphene half-life 30-36 hours, accumulates with repeated dosing, increasing risk of toxicity.
Hepatic via CYP3A4 mediated N-demethylation to norpropoxyphene, an active metabolite with similar analgesic but longer half-life; also undergoes O-demethylation and glucuronidation.
GFR 10-50 m L/min: Administer 65 mg every 6 hours; GFR <10 m L/min: Administer 65 mg every 8-12 hours.
GFR 10-50 m L/min: administer 65 mg every 6 hours; GFR <10 m L/min: avoid or reduce dose to 65 mg every 8 hours due to accumulation of norpropoxyphene.
WARNING: RISK OF SERIOUS CARDIOVASCULAR EVENTS AND DEATH. Propoxyphene has been associated with QT interval prolongation and serious cardiac toxicity, including fatal arrhythmias, especially at higher doses. The drug is contraindicated in patients with a history of QT prolongation, electrolyte abnormalities, or concurrent use of QT-prolonging drugs. Because of its cardiac toxicity, propoxyphene should be reserved for patients for whom alternative analgesics are ineffective or not tolerated. FDA has withdrawn propoxyphene from the market (2010); however, this warning applies to historical use.
Propoxyphene hydrochloride crosses the placenta. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but risk cannot be excluded. Second and third trimesters: Chronic use may lead to fetal dependence and withdrawal (neonatal abstinence syndrome). Near term: Use may cause neonatal respiratory depression if administered shortly before delivery.
FDA Pregnancy Category C. First trimester: Limited data, but no clear evidence of major malformations. Second and third trimesters: Risk of neonatal respiratory depression and withdrawal if used near term or in high doses. Chronic use may lead to neonatal opioid withdrawal syndrome.
Propoxyphene is a weak mu-opioid agonist; its efficacy is comparable to aspirin or acetaminophen for mild pain. It has a narrow therapeutic index; overdose can cause fatal cardiotoxicity (prolonged QTc and wide-complex tachycardia) and seizures, especially at modest dose increases. Due to toxicity and limited efficacy, it was withdrawn from the US market in 2010. Avoid in elderly, renal impairment, or history of cardiac arrhythmias. Naloxone is ineffective for propoxyphene-induced cardiotoxicity; treatment includes sodium bicarbonate for wide QRS.
Darvon (propoxyphene) is a weak opioid analgesic; due to risk of QT prolongation and cardiac arrhythmias, it was withdrawn from the US market in 2010. Consider monitoring ECG in patients with cardiac history or concurrent use of QT-prolonging agents. Propoxyphene has a narrow therapeutic index; overdose can cause seizures, respiratory depression, and cardiac toxicity. Combination with alcohol or CNS depressants increases risk of fatal respiratory depression.
No interactions on record
No interactions on record
PROPOXYPHENE HYDROCHLORIDE and DARVON are distinct pharmacological agents. PROPOXYPHENE HYDROCHLORIDE belongs to the Opioid Analgesic class and is primarily used for Management of mild to moderate painOff-label: chronic pain (historical use). DARVON belongs to the Opioid Analgesic class and is primarily used for Management of mild to moderate pain. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. PROPOXYPHENE HYDROCHLORIDE carries a safety status of Category C, whereas DARVON safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Primarily hepatic via CYP3A4 isoenzyme, with major metabolite norpropoxyphene (which contributes to cardiotoxicity).
Primarily renal (70-90% as unchanged drug and metabolites, including norpropoxyphene); biliary/fecal excretion accounts for less than 10%.
Primarily hepatic metabolism to norpropoxyphene, then renal excretion of metabolites; <20% excreted unchanged in urine; minor biliary/fecal elimination.
Approximately 80%, primarily to albumin.
Approximately 80% bound primarily to albumin.
Approximately 16 L/kg (0.16 L/kg for parent drug; high for metabolite norpropoxyphene due to tissue binding).
12-26 L/kg; high Vd indicates extensive tissue distribution.
Oral: 30–70% due to extensive first-pass hepatic metabolism.
Oral: 30-70% due to first-pass metabolism; erratic and variable.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% (e.g., 32.5 mg every 4 hours); Child-Pugh Class C: Avoid use.
Child-Pugh class B or C: contraindicated; mild hepatic impairment: reduce dose to 65 mg every 6 hours and monitor closely.
Not recommended for pediatric patients due to risk of respiratory depression and lack of safety data.
Not recommended for children under 12 years; for older children: 0.5-1 mg/kg/dose every 4 hours as needed, maximum 2 mg/kg/day.
Initiate at 65 mg every 6-8 hours; monitor for CNS effects and constipation; maximum 390 mg per day.
Initiate at 65 mg every 6 hours; monitor for respiratory depression, dizziness, and constipation; avoid in elderly with renal or hepatic impairment.
Propoxyphene is associated with fatal respiratory depression, especially when used in doses higher than recommended or in patients with respiratory compromise. Due to the risk of overdose and QT interval prolongation, propoxyphene was withdrawn from the U. S. market in 2010.
Risk of QT prolongation and fatal arrhythmias; opioid-induced respiratory depression; abuse potential; dependence and withdrawal; CNS depression; hepatic impairment; renal impairment; concurrent use of alcohol or other CNS depressants; elderly patients; use in pregnancy and lactation.
Hypersensitivity to propoxyphene or any component; significant respiratory depression; acute or severe bronchial asthma; known or suspected paralytic ileus; concomitant use with MAO inhibitors; QT prolongation or concomitant QT-prolonging drugs; electrolyte abnormalities (hypokalemia, hypomagnesemia); use during or within 14 days following MAOI therapy
No specific food interactions have been reported for propoxyphene hydrochloride. However, alcohol consumption should be strictly avoided due to additive CNS depression and potential for increased hepatotoxicity.
Grapefruit and grapefruit juice may increase propoxyphene levels; avoid concurrent consumption. Alcohol consumption is contraindicated due to additive CNS depression and increased risk of hepatotoxicity.
Propoxyphene is excreted into human breast milk. M/P ratio: approximately 0.5–1.0 (low). In infants, estimated daily dose via milk is <2% of maternal weight-adjusted dose. American Academy of Pediatrics considers it compatible with breastfeeding but warn against prolonged use due to potential CNS depression in infant and risk of dependence. Monitor infant for sedation, poor feeding.
Enters breast milk. M/P ratio approximately 1.0. Use caution; monitor infant for drowsiness, respiratory depression, and poor feeding. American Academy of Pediatrics considers use compatible with breastfeeding with careful monitoring.
Pregnancy may increase clearance of propoxyphene (due to increased hepatic blood flow and enzymatic induction), potentially reducing serum concentrations. However, dose adjustments are not routinely recommended due to lack of robust data and safety concerns. Avoid above recommended doses; use lowest effective dose for shortest duration. Note: propoxyphene is withdrawn in many markets due to cardiac toxicity; alternatives preferred.
Pharmacokinetic changes: increased clearance and volume of distribution, potentially requiring dose increases to maintain analgesia. Taper slowly to avoid withdrawal; use lowest effective dose for shortest duration.
Take exactly as prescribed; do not exceed the recommended dose due to risk of serious heart problems or seizures.,Propoxyphene may cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Do not consume alcohol or other CNS depressants while taking this medication.,This medication can be habit-forming; use only for the prescribed duration.,Keep out of reach of children; accidental overdose can be fatal even with small amounts.,Do not stop abruptly without consulting your doctor to avoid withdrawal symptoms.,Report symptoms like palpitations, fainting, or seizures immediately.
Do not exceed prescribed dose as overdose can be life-threatening.,Avoid alcohol and other CNS depressants while taking this medication.,May cause dizziness or drowsiness; avoid driving or operating machinery until effects are known.,Take exactly as prescribed; do not share with others.,Seek emergency care for signs of overdose: slow breathing, severe drowsiness, or fainting.